However, the cut-off value for PD-L1 expression is controversial, as demonstrated in a recent study in non-small cell lung cancer.12 Intratumor heterogeneity may be part of the explanation for this controversy and could invalidate the use of PD-L1 expression as a predictive marker for treatment selection. The gene discussed is CD274; the disease is non-small cell lung carcinoma.